Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome. Issue 1 (March 2019)

• Record Type: Journal Article
• Authors: Chua, Chong Chyn; Fleming, Shaun; Wei, Andrew H.
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 32:Issue 1(2019)
• Page Start: 3
• Page End: 12
• Publication Date: 2019-03
• Subjects: Therapy-related myeloid neoplasm -- t-AML -- t-MDS -- TP53 -- Clonal hematopoiesis; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2019.02.007
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: Therapy-related myeloid neoplasm (t-MN) is a rare but devastating consequence of chemotherapy and/or radiotherapy used for the treatment of solid cancers and various hematologic malignancies. Our current understanding of the etiology is that hematopoietic clones that are contemporaneous with the primary cancer and resistant to the cytotoxic exposure have the potential to undergo selective expansion and transformation to t-MN. Consequently, a large proportion of cases are associated with adverse risk factors, resulting in limited effective treatment options. Despite the emergence of some therapies with promising activity in t-MN, most effects are short-lived and allogeneic stem cell transplantation remains the only curative option for eligible patients. This review summarizes the current literature on t-AML and t-MDS, with the aim of providing practical recommendations on the clinical evaluation and management of these conditions.